相关实验视频
Updated: May 26, 2025

06:30
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
93
用tocilizumab治疗的类甲状腺性视觉神经病变
Endocrinology, diabetes & metabolism case reports
|February 22, 2025
概括
当类固醇等标准疗法不适合时,托西利祖马布为甲状腺光学神经病变 (DON) 提供了潜在的治疗方法. 这种干白素-6受体抑制剂在Graves病患者中显示出有前途.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
背景情况:
- 甲状腺视神经病变 (DON) 是Graves轨道病变 (GO) 的严重并发症.
- 标准治疗方法,包括高剂量类固醇和手术,不适合所有患者.
- 葡萄糖皮质类药物在同时存在中央血清性胆色素变异症 (CSC) 的患者中是禁忌的.
研究的目的:
- 评估托西利祖马布在DON患者的疗效和安全性以及标准治疗的禁忌.
- 探索托西利祖马布作为DON的替代治疗方法.
主要方法:
- 一名患有DON和CSC的患者接受了静脉注射托西利祖马布 (每4周服用6剂8mg/kg).
- 评估了疾病的严重程度和炎症.
- 磁共振成像 (MRI) 用于评估肌肉炎症.
主要成果:
- 患者的DON在托西利祖马布治疗后改善到中度至重度的GO.
- 核磁共振扫描显示,受影响肌肉的炎症显著减少.
- 在治疗期间没有观察到任何不良反应.
结论:
- 托西利祖马布在不适合标准治疗的DON患者中显示出临床改善和良好的安全性.
- 以前的病例报告和观察性研究支持托西利祖马布在DON的疗效.
- 托西利祖马布可能是DON的可行的治疗选择,特别是当葡萄糖皮质类药物不合适时,但需要进一步的高质量研究.
相关概念视频
Open Angle Glaucoma: Treatment
384
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
384
Angle Closure Glaucoma: Treatment
429
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
429
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
131
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
131
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
Myasthenia Gravis: Overview and Treatment
1.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.1K

